Report cover image

Global Influenza NA Inhibitor Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 91 Pages
SKU # APRC20355000

Description

Summary

According to APO Research, The global Influenza NA Inhibitor market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Influenza NA Inhibitor include ATK Chemical, Chemwill Asia Co.,Ltd., Green Cross, Moksha8 Pharma, NeoPharm, Shionogi Co., GlaxoSmithKline, Henan DaKen Chemical and Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Influenza NA Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza NA Inhibitor.

The Influenza NA Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza NA Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Influenza NA Inhibitor Segment by Company

ATK Chemical
Chemwill Asia Co.,Ltd.
Green Cross
Moksha8 Pharma
NeoPharm
Shionogi Co.
GlaxoSmithKline
Henan DaKen Chemical
Roche

Influenza NA Inhibitor Segment by Type

Zanamivir
Peramivir
Oseltamivir

Influenza NA Inhibitor Segment by Application

Influenza A Treatment
Influenza B Treatment

Influenza NA Inhibitor Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza NA Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza NA Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza NA Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Influenza NA Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

91 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Influenza NA Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Influenza NA Inhibitor Sales Estimates and Forecasts (2020-2031)
1.3 Influenza NA Inhibitor Market by Type
1.3.1 Zanamivir
1.3.2 Peramivir
1.3.3 Oseltamivir
1.4 Global Influenza NA Inhibitor Market Size by Type
1.4.1 Global Influenza NA Inhibitor Market Size Overview by Type (2020-2031)
1.4.2 Global Influenza NA Inhibitor Historic Market Size Review by Type (2020-2025)
1.4.3 Global Influenza NA Inhibitor Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Influenza NA Inhibitor Sales Breakdown by Type (2020-2025)
1.5.2 Europe Influenza NA Inhibitor Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Influenza NA Inhibitor Sales Breakdown by Type (2020-2025)
1.5.4 South America Influenza NA Inhibitor Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Influenza NA Inhibitor Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Influenza NA Inhibitor Industry Trends
2.2 Influenza NA Inhibitor Industry Drivers
2.3 Influenza NA Inhibitor Industry Opportunities and Challenges
2.4 Influenza NA Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Influenza NA Inhibitor Revenue (2020-2025)
3.2 Global Top Players by Influenza NA Inhibitor Sales (2020-2025)
3.3 Global Top Players by Influenza NA Inhibitor Price (2020-2025)
3.4 Global Influenza NA Inhibitor Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Influenza NA Inhibitor Major Company Production Sites & Headquarters
3.6 Global Influenza NA Inhibitor Company, Product Type & Application
3.7 Global Influenza NA Inhibitor Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Influenza NA Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 Influenza NA Inhibitor Players Market Share by Revenue in 2024
3.8.3 2023 Influenza NA Inhibitor Tier 1, Tier 2, and Tier 3
4 Influenza NA Inhibitor Regional Status and Outlook
4.1 Global Influenza NA Inhibitor Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Influenza NA Inhibitor Historic Market Size by Region
4.2.1 Global Influenza NA Inhibitor Sales in Volume by Region (2020-2025)
4.2.2 Global Influenza NA Inhibitor Sales in Value by Region (2020-2025)
4.2.3 Global Influenza NA Inhibitor Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Influenza NA Inhibitor Forecasted Market Size by Region
4.3.1 Global Influenza NA Inhibitor Sales in Volume by Region (2026-2031)
4.3.2 Global Influenza NA Inhibitor Sales in Value by Region (2026-2031)
4.3.3 Global Influenza NA Inhibitor Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Influenza NA Inhibitor by Application
5.1 Influenza NA Inhibitor Market by Application
5.1.1 Influenza A Treatment
5.1.2 Influenza B Treatment
5.2 Global Influenza NA Inhibitor Market Size by Application
5.2.1 Global Influenza NA Inhibitor Market Size Overview by Application (2020-2031)
5.2.2 Global Influenza NA Inhibitor Historic Market Size Review by Application (2020-2025)
5.2.3 Global Influenza NA Inhibitor Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Influenza NA Inhibitor Sales Breakdown by Application (2020-2025)
5.3.2 Europe Influenza NA Inhibitor Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Influenza NA Inhibitor Sales Breakdown by Application (2020-2025)
5.3.4 South America Influenza NA Inhibitor Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Influenza NA Inhibitor Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 ATK Chemical
6.1.1 ATK Chemical Comapny Information
6.1.2 ATK Chemical Business Overview
6.1.3 ATK Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
6.1.5 ATK Chemical Recent Developments
6.2 Chemwill Asia Co.,Ltd.
6.2.1 Chemwill Asia Co.,Ltd. Comapny Information
6.2.2 Chemwill Asia Co.,Ltd. Business Overview
6.2.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
6.2.5 Chemwill Asia Co.,Ltd. Recent Developments
6.3 Green Cross
6.3.1 Green Cross Comapny Information
6.3.2 Green Cross Business Overview
6.3.3 Green Cross Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Green Cross Influenza NA Inhibitor Product Portfolio
6.3.5 Green Cross Recent Developments
6.4 Moksha8 Pharma
6.4.1 Moksha8 Pharma Comapny Information
6.4.2 Moksha8 Pharma Business Overview
6.4.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
6.4.5 Moksha8 Pharma Recent Developments
6.5 NeoPharm
6.5.1 NeoPharm Comapny Information
6.5.2 NeoPharm Business Overview
6.5.3 NeoPharm Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 NeoPharm Influenza NA Inhibitor Product Portfolio
6.5.5 NeoPharm Recent Developments
6.6 Shionogi Co.
6.6.1 Shionogi Co. Comapny Information
6.6.2 Shionogi Co. Business Overview
6.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
6.6.5 Shionogi Co. Recent Developments
6.7 GlaxoSmithKline
6.7.1 GlaxoSmithKline Comapny Information
6.7.2 GlaxoSmithKline Business Overview
6.7.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
6.7.5 GlaxoSmithKline Recent Developments
6.8 Henan DaKen Chemical
6.8.1 Henan DaKen Chemical Comapny Information
6.8.2 Henan DaKen Chemical Business Overview
6.8.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
6.8.5 Henan DaKen Chemical Recent Developments
6.9 Roche
6.9.1 Roche Comapny Information
6.9.2 Roche Business Overview
6.9.3 Roche Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Roche Influenza NA Inhibitor Product Portfolio
6.9.5 Roche Recent Developments
7 North America by Country
7.1 North America Influenza NA Inhibitor Sales by Country
7.1.1 North America Influenza NA Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Influenza NA Inhibitor Sales by Country (2020-2025)
7.1.3 North America Influenza NA Inhibitor Sales Forecast by Country (2026-2031)
7.2 North America Influenza NA Inhibitor Market Size by Country
7.2.1 North America Influenza NA Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Influenza NA Inhibitor Market Size by Country (2020-2025)
7.2.3 North America Influenza NA Inhibitor Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Influenza NA Inhibitor Sales by Country
8.1.1 Europe Influenza NA Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Influenza NA Inhibitor Sales by Country (2020-2025)
8.1.3 Europe Influenza NA Inhibitor Sales Forecast by Country (2026-2031)
8.2 Europe Influenza NA Inhibitor Market Size by Country
8.2.1 Europe Influenza NA Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Influenza NA Inhibitor Market Size by Country (2020-2025)
8.2.3 Europe Influenza NA Inhibitor Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Influenza NA Inhibitor Sales by Country
9.1.1 Asia-Pacific Influenza NA Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Influenza NA Inhibitor Sales by Country (2020-2025)
9.1.3 Asia-Pacific Influenza NA Inhibitor Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Influenza NA Inhibitor Market Size by Country
9.2.1 Asia-Pacific Influenza NA Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Influenza NA Inhibitor Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Influenza NA Inhibitor Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Influenza NA Inhibitor Sales by Country
10.1.1 South America Influenza NA Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Influenza NA Inhibitor Sales by Country (2020-2025)
10.1.3 South America Influenza NA Inhibitor Sales Forecast by Country (2026-2031)
10.2 South America Influenza NA Inhibitor Market Size by Country
10.2.1 South America Influenza NA Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Influenza NA Inhibitor Market Size by Country (2020-2025)
10.2.3 South America Influenza NA Inhibitor Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Influenza NA Inhibitor Sales by Country
11.1.1 Middle East and Africa Influenza NA Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Influenza NA Inhibitor Sales by Country (2020-2025)
11.1.3 Middle East and Africa Influenza NA Inhibitor Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Influenza NA Inhibitor Market Size by Country
11.2.1 Middle East and Africa Influenza NA Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Influenza NA Inhibitor Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Influenza NA Inhibitor Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Influenza NA Inhibitor Value Chain Analysis
12.1.1 Influenza NA Inhibitor Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Influenza NA Inhibitor Production Mode & Process
12.2 Influenza NA Inhibitor Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Influenza NA Inhibitor Distributors
12.2.3 Influenza NA Inhibitor Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.